IU Health Deploys New Brain Cancer Imaging Drug

The Indianapolis health system is the first in the U.S. to use the FDA-approved imaging agent Pixclara.

Updated on Oct. 20, 2026 in Cancer

IU Health Deploys New Brain Cancer Imaging Drug

Live Poll

Do you believe new diagnostic imaging technologies are effectively improving cancer treatment outcomes?

Indiana University Health has begun administering Pixclara, an FDA-approved imaging drug designed for both adults and children with suspected recurrent glioma. The treatment allows physicians to more accurately distinguish between tumor recurrence and side effects from previous cancer treatments.

Why it matters

The ability to clearly differentiate between cancer regrowth and post-treatment inflammation is critical for determining subsequent clinical care pathways. This advanced diagnostic capability helps providers avoid unnecessary interventions while ensuring patients receive timely, targeted treatment.

Pixclara is officially indicated for identifying recurrent glioma in adults and pediatric patients. Its adoption follows the launch of a new diagnostics facility supported by a $20 million philanthropic gift.

The players

Indiana University Health

Indiana University Health is a comprehensive academic health system operating various medical centers throughout the state of Indiana.

The details

Physicians at IU Health utilize the imaging agent to evaluate complex scan results, providing clarity in cases where treatment effects mimic tumor growth. This implementation is supported by the system's new Theranostics Center of Excellence, which provides specialized infrastructure for advanced diagnostic services.

August 2026: IU Health launched the Theranostics Center of Excellence.
October 6, 2026: IU Health announced the deployment of Pixclara.
October 19, 2026: Date of article publication.

Cancer
Oct. 22
Indiana University Opens Neuro-Oncology Research Center
People
Oct. 12
IU Health Appointed Luke Taylor Assistant CFO
Saving
Oct. 20
Indianapolis Council Approves 2027 Budget

The Big Picture

The Theranostics Center of Excellence facilitates the use of targeted radiopharmaceuticals and advanced imaging agents for precise oncology diagnosis and treatment. The implementation of Pixclara follows the establishment of this center, marking an expansion of its specialized diagnostic capabilities.

Patients with suspected recurrent glioma in Indianapolis may now access enhanced imaging that provides greater diagnostic accuracy. This development potentially reduces the need for invasive biopsies or unnecessary follow-up procedures by better characterizing brain lesions.

The takeaway

Advanced imaging agents like Pixclara represent a shift toward more precise non-invasive monitoring in neuro-oncology. Patients should consult their specialists to determine if this new diagnostic tool is appropriate for their specific treatment plan.